Phase 1/2Completed
AllogeneiC Human Mesenchymal Stem Cells (hMSC) in Patients With Aging FRAilTy Via IntravenoUS Delivery (CRATUS)
A Phase I/II, Randomized, Blinded and Placebo-controlled Trial to Evaluate the Safety and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion in Patients With Aging Frailty
- Sponsor
- Longeveron Inc. (Industry)
- Enrolment
- 65 enrolled
- Conditions
- Frailty
- Interventions
- Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs); Placebo; Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)
- Ages
- adults, older adults
- Registry
- NCT02065245
From the registry
The purpose of this study is to look at the safety of treatment with stem cells in patients with Frailty.
Primary outcomes
- Incidence of Any Treatment Emergent - Serious Adverse Events (TE-SAEs)